AR059293A1 - Derivados de aminoindazol, procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de aminoindazol, procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR059293A1 AR059293A1 ARP070100442A ARP070100442A AR059293A1 AR 059293 A1 AR059293 A1 AR 059293A1 AR P070100442 A ARP070100442 A AR P070100442A AR P070100442 A ARP070100442 A AR P070100442A AR 059293 A1 AR059293 A1 AR 059293A1
- Authority
- AR
- Argentina
- Prior art keywords
- so2a
- so2n
- hal
- con
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Los compuestos de la presente pueden utilizarse, por ejemplo, para el tratamiento del cáncer. Procesos de obtencion de los mismos. Reivindicacion 1: Compuestos de la formula (1) en donde R1 y R2 son, de modo independiente entre si, H, A, - [C(R5)2]nN (R5)2, -[C(R5)2]N(R5)2[C(R5)2]nOR5, -[C(R5)2]nCOOR5, -[C(R5)2]nAr, - [C(R5)2]nHet, -[C(R5)2]nC:::CH, -O-[C(R5)2]nC:::CH, - [C(R5)2]nCON(R5)2, -[C(R5)2]nCONR5N(R5)2, -COAr, -COHet, -COA, CHO, -CO-C:::CR5, -SOAr, -SOHet, -SOA, -SO-C:::CR5, - SO2Ar, -SO2Het, -SO2A, -SO2-C:::CR5, -SO2N(R5)2, -SO2NHAr, -SO2NHHet, -SO2NH-C:::CR5, -SO2NAAr, -SO2NAHet, SO2NA-C:::CR5, -CON(R5)2, -CONHAr, -CONHHet, -CONH-C:::CR5, -CONAAr, -CONAHet o -CONA-C:::CR5, R3 es H o A, R4 es H, A, -[C(R5)2]nAr o - [C(R5)2]nHet, X es -(E)-CR5=CR5-, -( E )-CHal=CHal-, -C:::C-, Ar-diílo o Het1-diílo, Y es H, A, Ar, Het, -C(R5)2Ar o C(R5)2Het, Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con Hal, A, OR5, SR5, N(R5)2, NO2, CN, COOR, CON(R5)2, NR5COA, NR5CON(R5)2, NR5SO2A, COR5, SO2N(R5)2, S(O)mA, -[C(R5)2]n-COOR5 y/u -O[C(R5)2]o-COOR5, Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CON(R5)2, SO2N(R5)2, N(R5)2, OCON(R5)2, NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCON(R5)2, NACON(R5)2, SO2A, =S, =NH, =NA y/u =O (oxígeno del carbonilo), Het1 es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con A, OA, OH, SH, SA, Hal, NO2, CN, (CH2)nCOOH, (CH2)nCOOA, CHO, COA, SO2A, CON(R5)2, SO2N(R5)2, N(R5)2, OCON(R5)2, NHCOA, NHCOOA, NACOOA, NHSO2OA, NASO2OA, NHCON(R5)2, NACON(R5)2, -SO2A, =S, =NH, =NA y/u =O (oxígeno del carbonilo), R5 es H o A; A es alquilo C1-10, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o Cl. Hal es F, Cl, Br o I; m es 0, 1 o 2, n es 0, 1, 2, 3, 4 o 5, o es 0, 1 o 2, así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006005179A DE102006005179A1 (de) | 2006-02-06 | 2006-02-06 | Aminoindazolderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059293A1 true AR059293A1 (es) | 2008-03-26 |
Family
ID=38282156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100442A AR059293A1 (es) | 2006-02-06 | 2007-02-02 | Derivados de aminoindazol, procesos de obtencion y composiciones farmaceuticas. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090036508A1 (es) |
EP (1) | EP1981879A1 (es) |
JP (1) | JP2009525996A (es) |
AR (1) | AR059293A1 (es) |
AU (1) | AU2007214086A1 (es) |
CA (1) | CA2641350A1 (es) |
DE (1) | DE102006005179A1 (es) |
IL (1) | IL193210A0 (es) |
WO (1) | WO2007090494A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
US7956051B2 (en) | 2008-01-24 | 2011-06-07 | Allergan, Inc. | Therapeutic amides and related compounds |
CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
DE102008038222A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
AT509045B1 (de) | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
KR101125334B1 (ko) | 2010-04-09 | 2012-03-27 | 엘지이노텍 주식회사 | 발광 소자, 발광 소자 제조방법 및 발광 소자 패키지 |
EP2640386B1 (en) | 2010-11-16 | 2017-01-18 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1280878B (de) * | 1961-11-30 | 1968-10-24 | Smith Kline French Lab | 3-Aminoindazole |
USRE28939E (en) * | 1961-11-30 | 1976-08-24 | Smithkline Corporation | 3-Aminoindazole derivatives |
AU2002353186A1 (en) * | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
BR0311291A (pt) * | 2002-05-17 | 2005-03-29 | Pharmacia Italia Spa | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos |
NZ539193A (en) * | 2002-09-05 | 2008-04-30 | Aventis Pharma Sa | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
EP1572200B1 (fr) * | 2002-12-12 | 2011-08-17 | Aventis Pharma S.A. | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
-
2006
- 2006-02-06 DE DE102006005179A patent/DE102006005179A1/de not_active Withdrawn
-
2007
- 2007-01-10 WO PCT/EP2007/000172 patent/WO2007090494A1/de active Application Filing
- 2007-01-10 EP EP07702672A patent/EP1981879A1/de not_active Withdrawn
- 2007-01-10 US US12/278,325 patent/US20090036508A1/en not_active Abandoned
- 2007-01-10 CA CA002641350A patent/CA2641350A1/en not_active Abandoned
- 2007-01-10 JP JP2008553640A patent/JP2009525996A/ja active Pending
- 2007-01-10 AU AU2007214086A patent/AU2007214086A1/en not_active Abandoned
- 2007-02-02 AR ARP070100442A patent/AR059293A1/es unknown
-
2008
- 2008-08-03 IL IL193210A patent/IL193210A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007090494A1 (de) | 2007-08-16 |
CA2641350A1 (en) | 2007-08-16 |
US20090036508A1 (en) | 2009-02-05 |
IL193210A0 (en) | 2009-02-11 |
AU2007214086A1 (en) | 2007-08-16 |
DE102006005179A1 (de) | 2007-08-09 |
EP1981879A1 (de) | 2008-10-22 |
JP2009525996A (ja) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059293A1 (es) | Derivados de aminoindazol, procesos de obtencion y composiciones farmaceuticas. | |
AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
AR085110A1 (es) | Derivados de 7-azaindol | |
AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
PE20141678A1 (es) | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina | |
AR082728A1 (es) | Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos | |
AR092568A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
AR083670A1 (es) | DERIVADOS DE 7-([1,2,3]TRIAZOL-4-IL)-PIRROLO[2,3-b]PIRAZINA UTILES COMO INHIBIDORES DE LA PROLIFERACION CELULAR, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCEDIMIENTO PARA PREPARARLOS | |
AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
AR076006A1 (es) | Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen. | |
PE20171624A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
AR070212A1 (es) | Derivados de 4-(pirrolo[2,3-c]piridin-3-il)-pirimidinil-2-amina, proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores, metastasis tumoral y/o sida. | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
CR20110059A (es) | Compuestos organicos | |
AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos | |
AR077567A1 (es) | Derivados de aminopiridina | |
AR096235A1 (es) | Arilquinazolinas | |
AR092211A1 (es) | Derivados de hidropirrolopirrol | |
AR082109A1 (es) | Derivados de bipiridilo | |
RS54773B1 (sr) | Pirano [3,2-d][1,3] tiazol kao inhibitor glukozidaze | |
AR103199A1 (es) | N-alquilaril-5-oxiaril-octahidrociclopenta[c]pirrol moduladores alóstericos negativos de nr2b | |
PE20160120A1 (es) | Derivados de nucleosido 4'-fluoro-2'-metilo sustituido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |